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ABSTRACT 
Pharmacological intervention is the commonest mode of managing patients with schizophrenia. 
Both clinicians and patients are concerned that antipsyohotic drugs are costly and contribute to 
poor drug compliance in India. This study compared the equivalent doses of antipsychotic drugs 
and their costs across brands. Results show that antipsychotic drugs are affordable and are 
comparable to drug treatment costs of other physical illnesses. However, coprescription of drugs 
add to the burden. Numerous brands and a 2-2Vz fold difference in cost raises many concerns 
including that of drug bioavailability. Hence, the authors recommend consensus and formulation of 
guidelines for the pharmacological management of schizophrenia. 
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Schizophrenia has always been one of the 
most devastating groups of psychiatric illnesses, 
taking its toll on afflicted individuals as well as 
their families. Schizophrenia has been compared 
to chronic medical illnesses such as diabetes, 
albeit more complex (Kane and McGlashan, 
1995). Treatment of this chronic, often 
progressing and deteriorating disorder has posed 
a great challenge, especially since the 
introduction of antipsychotic medications. 
Treatment of schizophrenia occurs at the 
individual level, family level and at the level of 
the community. Individual level intervention 
consists of pharmacological treatment, 
counselling and vocational rehabilitation. It is 
difficult to assess the treatment of schizophrenia 
in terms of cost benefit. Costs and outcomes 
are not the same for everyone. As problems and 
needs vary, so too will costs. Problems of an 
individual and family include ill-health, difficult 
behaviours, social skills deficits, and quality of 
life more generally. Costs can be estimated at 
three levels-individual user cost functions* or 
prediction, facility level cost functions, and 
system-level cost functions estimated for 
organizations or localities as a whole. Studies in 
the US have shown that the societal burden of 
schizophrenia was estimated to be $32.5 billion 
in 1990 out of which $17.9 billion was only 
towards treatment costs and $14.6 billion towards 
productivity loss (National Mental Health 
Advisory Council, 1993). 
Ever since the discovery of 
chlorpromazine (CPZ), there has been a constant 
search for newer antipsychotic drugs. Issues of 
costs as well as comparability across different 
antipsychotic drugs in terms of efficacy and side 
effect profile and factors influencing compliance 
have been important factors influencing the 
choice of antipsychotic drugs. These issues have 
become even more relevant with the introduction 
of the 'newer antipsychotic drugs'. In the 1970's 
there were about 5 companies manufacturing 
antipsychotic drugs (Current Index of Medical 
Sciences, CIMS, 1970). This number has grown 
more than eightfold presently (CIMS, 1998). CPZ 
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for instance is manufactured by at least 20 
companies and marketed under different brand 
names. Recently risperidone has been 
introduced by at least 10 companies. 
While only 4-5 antipsychotic drugs were 
available in India in the 1970's(CIMS, 1970), over 
the last two decades this number has increased 
to about 12 (Drug Index, 1998), The number of 
brands available currently for each antipsychotic 
drug has steadily increased. With the influx of so 
many brands, it becomes increasingly necessary 
to examine issues of comparability across 
different pharmacological agents as well as 
individual user costs and discuss other issues that 
influence prescribing and compliance. 
MATERIAL AND METHOD 
A. Assessment of comparability : Drug 
equivalents in terms of oral CPZ were tabulated 
from i) drug company literature - CIMS., Drug 
Index., and Monthly Index of Medical Sciences 
(MIMS), ii) the British National Formulary (1998), 
and iii) review of articles comparing different 
antipsychotic drugs {Comprehensive Text Book 
of Psychiatry, Sadock & Kaplan (1995), 
Psychopharmacology 4th generation, Bloom & 
Kuffer (1995), and Lehman & Steinwachs,1998)}. 
B. Assessment of cost : The prices of 
some ofthe commonly used antipsychotic drugs 
were compiled from the following sources : 
1. The Consumers Cooperative Society at the 
National Institute of Mental Health and Neuro 
Sciences, Bangalore, where medications are 
available at a slightly subsidized rate. 
2. The cash pharmacy, a government run 
dispensing unit in Bangalore. 
The prices were listed as per the 
availability of different drug brands. 
RESULTS 
The drug equivalents of all commonly 
available oral antipsychotic drugs in terms of CPZ 
100 mg are specified in table 1. The equivalent 
dose of depot neuroleptics are presented in table 
2. Table 3 provides the dose equivalence of depot 
and oral antipsychotic drugs. 
The prices ofthe commonly available oral 
antipsychotic drugs and the monthly expenditure 
for maintenance dose of 300 mg CPZ per day 
compiled in table 1. The cost-index (ratio of 
highest price to lowest) of each antipsychoticdrug 
across different brands is also depicted in table-1. 
Table-1 also shows the relative cost of each 
antipsychotic drug compared to CPZ. Similarly 
the cost of available depot neuroleptics have been 
compared against the reference maintenance 
dose of 300 mg CPZ per day (Table 2). 
DISCUSSION 
Schizophrenia is one of the commonest 
disorders seen by practising psychiatrists. 
Although schizophrenia affects less than 1% of 
the US population, the total costs of this severe 
mental disorder consumes 22% of the costs of 
all mental illnesses (Zito et al., 1998). Several 
carefully conducted cost studies have indicated 
that care in community is generally cheaperthan 
care in a hospital, although none of these studies 
indicate that it is better (Goldberg, 1991). Cost 
functions are useful when evaluating, planning 
or purchasing alternative strategies or modes of 
care. However, no such studies comparing 
various drugs nor the models for treating 
schizophrenia have been carried out in our 
population. The various antipsychotic drugs that 
are available have helped significantly in 
symptom control. However, a surge in the 
availability of different antipsychotic drugs raises 
issues of drug choice and dose comparability. 
The clinicians prescription must be governed as 
much by the patient's purse as by the patient's 
need (Channabasavanna, 1996). 
A comparison of cost of different 
antipsychotic drugs show that the monthly cost 
of maintenance with CPZ (300 mg) is Rs.55/-
and that of trifluoperazine is Rs.25/- (the relative 
cost=0.45, table-1). Newer drugs like risperidone 
(4 mg/day) and clozapine (200 mg/day) costs 
as low as Rs.60/- and Rs.225/- per month 
respectively for the maintenance dose equivalent 
of CPZ (300 mg/day). In UK, newer 
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TABLE -1 
DOSE EQUIVALENTS OF ANTIPSYCHOTIC DRUGS AND THEIR APPROXIMATE COST 
Drug* 
ChhxpfomaanB 
Haloperidol 
Trifluoperazine 
Pimozide 
Thioridazine 
Loxapine 
Flupenthixol 
Risperidone 
Clozapine 
CPZ Equ(A) 
(100 mg/day) 
100 
2-3 
5 
1.5 
100 
10-20 
3 
0.6-1 
50 
Dose per tab. 
(mg) (B) 
100 
10 
10 
4 
100 
25 
3 
4 
100 
Price per 10 
Tab (Rs) (C) 
6-15 
20-40 
5-10 
20-50 
45-50 
70 
70 
20-500 
42-48 
Cost* per month 
(Rs) (Z) 
55-135 
35-70 
25-45 
70-170 
405-450 
210 
610 
60-1500 
225-300" 
Cost-
Index* 
'2.5 
2.0 
1.8 
2.4 
1.1 
-
-
25.0 
1.3 
Relative 
Cost" 
10 
0.6 
0.4 
1.3 
7.4 
3.8 
11.1 
1.1 
4.1 
' approximate cost of drugs as per month (Z) equivalent to 300 mg of CPZ/day {Z=90AxC+10B} 
" maintenance dose of 200 mg/day 
' ratio of maximum to minimum cost across brands 
** ratio of minimum cost of the antipsychotic drug per month to that of CPZ 
pharmacological therapies for schizophrenia are 
considerably more costly than previously existing 
treatments. For example, the approximate 
average cost for a 30-day treatment with 
clozapine is £168, for risperidone £112. This 
compares with less than £30 for haloperidol 
(Davis and Drummond, 1993). 
Prices of antipsychotic drugs have 
reduced in the last five years. However, there 
still remains marked price differences across 
brands. There is an almost 2-2% fold difference 
in the price of drugs across various brands. 
Although partially explained by differing 
overhead costs across companies, this raises a 
concern among clinicians about the 
bioavailability across brands. There is 
competitiveness across pharmaceutical 
companies in order to offer the best product at 
the cheapest rate. To the clinician, this translates 
to maximum therapeutic efficacy at the minimum 
TABLE-2 
EQUIVALENT DOSES OF DEPOT NEUROLEPTICS 
Drug 
FluphenazJne 
decanoate 
Haloperidol 
decanoate 
Flupenthixol 
decanoate 
Dotage CPZ Equiv. Cost (Rs) 
(mg/day) per month 
25 mg 1000 40-6C 
•very 2 weeks 
100 mg 500 180-210 
every 4 weeks 
40mg 400 300 
every 2 weeks 
cost. Thus, bioavailability is a serious concern 
while prescribing. 
While on the face of it antipsychotic drugs 
seem 'affordable' the other costs associated with 
treatment make it more expensive. For example, 
antiparkinsonian agents are often co-prescribed. 
Antiparkinsonian agents are often more 
expensive than the antipsychotic drugs 
themselves. For example, the monthly cost of 
trihexyphenydyl (4mg/day) is Rs.20/- to Rs.50/-
(Drug Index, 1998). Similarly when 
antidepressants, anxiolytics, hypnotics and so 
on are co-prescribed the costs increase. 
The problem of cost is not exclusive for 
schizophrenia. Grossly, it appears that the cost of 
antipsychotic drugs is comparable to drug treatment 
costs of chronic physical illnesses such as 
tuberculosis, hypertension, diabetes and epilepsy. 
In summary, we have attempted to provide 
comparisons across various antipsychotic drugs. 
Our analysis of cost suggests that most of the 
antipsychotic drugs are affordable. However, 
treatment expenditure of comorbidity, side effects, 
TABLE-3 
CONVERSION OF ORAL TO PARENTERAL 
ANTIPSYCHOTICS 
* maintenance dose equivalent to 300 mg of CPZ per day 
Oral dose  Parenteral dose 
Fluphenazine 10 mg/day 
Haloperidol 10 mg/day 
Fkjpenthwol 6 mg/day 
12.5 mg every 2 weeks 
100 mg every 4 weeks 
20 mg every 2 weeks 
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and cost of consultation including travel add to 
the burden. This may in turn influence compliance. 
The wide variation in cost of different brands of 
the same drug is also of concern to both 
preservers and consumers. The issues raised in 
the article highlight several concerns and a need 
for action the most important being formulation 
of guidelines for pharmacological management 
of psychoses from an authorized body such as 
the Indian Psychiatric Society. For example, the 
Australian Legislative for the first time formulated 
guidelines including economic evaluation of a 
drug prior to government approval of new 
pharmaceutical products in addition to 
establishing efficacy and safety (Moscarelli, 
1998). The cost analysis for the treatment of 
schizophrenia should include a broad range of 
direct and indirect outcomes rather than focussing 
on direct medical cost of the alternative therapies. 
There should be systematic procedures for 
monitoring and enforcing guidelines for economic 
evaluation. The other concerns are : a need for 
judicious use of co-prescribed drugs, ensuring 
availability of antipsychotic drugs at least in all 
districts, and constant monitoring of bioavailability 
of different antipsychotic brands. 
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